Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV Achillion Pharmaceuticals.

Importantly, we believe ACH-2928 is effective in combination with NS3 protease inhibitors highly, NS5B polymerase inhibitors, ribavirin and interferon. Related StoriesJohns Hopkins doctors desire people to get vaccinated against influenza virusNew vaccine applicant shows great guarantee at fighting respiratory syncytial virusHiroshima University experts demonstrate how Sendai virus escapes sponsor immune systemMichael D. Kishbauch, Achillion’s President and CEO, stated, The nomination of this novel NS5A clinical candidate is both interesting and significant. We have initiated IND-enabling testing of ACH-2928, and intend to initiate combination treatment in 2011. The nomination of ACH-2928 is further evidence of our expertise in HCV medication discovery and structure-based style..Related StoriesBoston Children's Medical center selects Vijay G. Sankaran to get Rising Star AwardBoston Kids's and Rock Health synergy to accelerate development of pediatric wellness technologiesChildren's Memorial Hermann Hospital presents Halloween safety tips Acetadote has become a standard of look after treating acetaminophen poisoning in the U.S., and we are proud to work with Phebra to extend the product’s benefits to the Australian medical community, said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. Phebra’s founded distribution network and advertising experience with more than 70 hospital products gives us self-confidence in its capability to make this life-saving drug open to a broad target audience. We are also extremely pleased to mark Cumberland’s access into international markets with this important product release.